Biotechnology · Drug Discovery
Developing novel small molecule therapeutics targeting Sirtuin 6, a master regulator of aging and genomic stability, to address unmet needs in age-related diseases.
Explore Our ScienceMost Potent
Small molecule SIRT6 activators reported to date
In Vivo
Confirmed activity in C. elegans longevity models
Published
Peer-reviewed in ACS Medicinal Chemistry Letters, 2026
Watch
How SIRT6 decline drives the hallmarks of aging, and what happens when we restore it.
Our Science
Sirtuin 6 (SIRT6) is a NAD+-dependent deacetylase that plays a central role in DNA repair, metabolic homeostasis, and the regulation of aging. Loss of SIRT6 function leads to accelerated aging, genomic instability, and metabolic dysfunction, hallmarks of numerous age-related diseases.
Our proprietary platform is built on a novel class of chemical scaffolds. Through systematic medicinal chemistry, we have developed the most potent small molecule SIRT6 activators reported to date, with confirmed activity in C. elegans longevity models and clean toxicology profiles across our compound series.
Therapeutic Focus
SIRT6 activation offers broad therapeutic potential across age-related conditions.
Targeting fundamental mechanisms of biological aging through direct SIRT6 activation and enhanced DNA repair capacity.
Lead OptimizationHarnessing SIRT6's established role as a tumor suppressor to develop novel approaches for cancer intervention.
DiscoveryAddressing cartilage degradation and joint inflammation through SIRT6-mediated metabolic and epigenetic modulation.
DiscoveryRestoring metabolic balance by activating SIRT6 pathways that regulate glucose homeostasis and lipid metabolism.
DiscoveryResearch
"Among the most potent small molecule SIRT6 activators reported to date, with activity at concentrations as low as 2 μM."Read the Publication
Our Team
Co-Founder · Operations
Business development, strategic partnerships, and company operations. Leading CRO partner selection and international expansion for Virella's preclinical program.
Co-Founder · Science
Medicinal chemistry and SIRT6 biochemistry. Designed the griseofulvin-based SIRT6 activation platform and leads compound optimization and preclinical characterization.
Get in Touch
Whether you're a potential partner, investor, or researcher, we'd love to hear from you.